Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn

Pediatrics

Volumn 114, Issue 2 I, 2004, Pages 417-426

  Lorch, Scott A ^a,b,c   Cnaan, Avital ^a   Barnhart, Kurt ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Center for Psychotherapy Research   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; Inhaled nitric oxide; Neonate; Persistent pulmonary hypertension

Indexed keywords

NITRIC OXIDE;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; NEONATOLOGY; NEWBORN; NEWBORN PERIOD; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT, NEWBORN; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3442882170     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.114.2.417     Document Type: Article

References (39)

1. Lewit EM, Baker LS, Corman H, Shiono PH. The direct cost of low birth weight. Future Child. 1995;5:35-56
2. Boyle MH, Torrance GW, Sinclair JC, Horwood SP. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med. 1983;308:1330-1337
3. Mauskopf JA, Backhouse ME, Jones D, et al. Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: impact on hospital resource use and charges. J Pediatr. 1995;126:94-101
4. Phibbs CS, Phibbs RH, Wakeley A, Schlueter MA, Sniderman S, Tooley WH. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr. 1993;123:953-962
5. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr. 1995;126:421-426
6. Roberts TE. Economic evaluation and randomized controlled trial of extracorporeal membrane oxygenation: UK collaborative trial. The Extracorporeal Membrane Oxygenation Economics Working Group. BMJ. 1998;317:911-915
7. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-427
8. Halpern MT, Read JS, Ganoczy DA, Harris DR. Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1. AIDS. 2000;14:691-700
9. Mrus JM, Yi MS, Eckman MH, Tsevat J. The impact of expected HIV transmission rates on the effectiveness and cost of ruling out HIV infection in infants. Med Decis Making. 2002;22(suppl):S38-S44
10. Lee SK, Normand C, McMillan D, Ohlasson A, Vincer M, Lyons C. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med. 2001;155:387-395
11. Zupancic JA, Richardson DK, Lee K, McCormick MC. Economics of prematurity in the era of managed care. Clin Perinatol. 2000;27:483-497
12. Christou H, Van Marter LJ, Wessel DL, et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med. 2000;28:3722-3727
13. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N EngI J Med. 2000;342:469-474
14. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics. 1998;101:325-334
15. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597-604
16. Roberts JD Jr, Fineman JR, Morin FC III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:605-610
17. Wessel DL, Adatia I, Van Marter LJ, et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics. 1997;100(5). Available at: pediatrics.org/cgi/ content/full/100/5/e7
18. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2001(4):CD000399
19. Jacobs P, Finer NN, Robertson CM, Etches P, Hall EM, Saunders LD. A cost-effectiveness analysis of the application of nitric oxide versus oxygen gas for near-term newborns with respiratory failure: results from a Canadian randomized clinical trial. Crit Care Med. 2000;28:872-878
20. Jacobs P, Finer NN, Fassbender K, Hall E, Robertson CMT. Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: eighteen to 24-month follow-up for Canadian patients. Crit Care Med. 2002;30:2330-2334
21. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care. 1991;7:561-573
22. Cutler DM, Huckman RS. Technological development and medical productivity: the diffusion of angioplasty in New York state. J Health Econ. 2002;22:187-217
23. Cutler D, McClellan M. Is technological change in medicine worth it? Health Aff. 2001;20:11-29
24. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2-building a tree. Med Decis Making. 1997;17:126-135
25. Dolan P. Modeling valuations for EuroQOL health states. Med Care. 1997;35:1095-1108
26. Rogowski J. Measuring the cost of neonatal and perinatal care. Pediatrics. 1999;103:329-335
27. Kotagal UR, Perlstein PH, Atherton HD, Donovan EF. The influence of day of life in predicting the inpatient costs for providing care to very low birth weight infants. Am J Manag Care. 1997;3:217-225
28. Chalom R, Raphaely RC, Costarino AT Jr. Hospital costs of pediatric intensive care. Crit Care Med. 1999;27:2079-2085
29. Bureau of Labor Statistics. National Compensation Survey - Wages. Washington, DC: Government Printing Office; 2002
30. Centers for Medicare and Medicaid Services. National physician fee schedule relative valuefile. Washington, DC: Government Printing Office; 2002
31. Centers for Medicare and Medicaid Services. Clinical diagnostic laboratory fee schedule. Washington, DC: Government Printing Office; 2002
32. Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001
33. Bureau of Labor Statistics. Consumer Price Index. Washington, DC: Government Printing Office; 2002
34. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(suppl):S68-S80
35. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
36. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making. 1985;5:157-177
37. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making. 1986;6:85-92
38. Halpern EF, Weinstein MC, Hunink MGM, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making. 2000;20:314-322
39. St. John EB, Nelson KG, Cliver SP, Bishnoi RR, Goldenberg RL. Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol. 2000;182:170-175